Apnimed, Inc. (BOATS:APMD) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$220.8M in the latest tranche · US$16 a share · BofA Securities +3 Dealers: BofA Securities (co-lead), Evercore ISI (co-lead), Cantor (co-lead), LifeSci Capital (co-lead) Use of proceeds: To support commercial readiness and the potential U.S. launch of Oxnimbi, if approved by the FDA | Sep 8, 2026 |